Organization (Industry)
Pharmazz, Inc. (United States)
ClinicalTrials.gov lists Pharmazz, Inc. (United States) as lead sponsor of 14 trials. It has 13 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs. 2 trials are registered to start in 2027 or later.
This page covers Pharmazz, Inc. (United States): 14 lead-sponsored trials and 1 legal-entity registration.
Disease areas (14)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stroke | 4 |
| Hemorrhage | 2 |
| Hypoxia | 2 |
| Alzheimer Disease | 1 |
| Asphyxia Neonatorum | 1 |
Showing 5 of 14 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 1 |
| 2014 | 1 |
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (13)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sovateltide | Brain Injuries | Phase 3 | 1 |
| Sovateltide | Ischemic Stroke | Phase 3 | 1 |
| Sovateltide | Brain Injuries, Traumatic | Phase 3 | 1 |
| PMZ-1620 (sovateltide) along with standard treatment | Stroke | Phase 3 | 2 |
| PMZ-1620 (sovateltide) along with standard treatment | Cerebral Infarction | Phase 3 | 1 |
Showing 5 of 13 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Centhaquine | 4 |
| Sovateltide | 3 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 3 of 3 hit target (n=3) | 1 of 3 on time (n=3) |
Journals published in (25)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Brain research | 3 |
| Drugs | 3 |
| The Journal of surgical research | 3 |
| Drug research | 2 |
| International journal of molecular sciences | 2 |
Showing 5 of 25 journals.
Financing and grant events (7)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-05-27 | Private placement | 10,037,500 | Form d |
| 2024-08-15 | Private placement | 7,500,000 | Form d |
| 2024-02-02 | Private placement | 150,000 | Form d |
| 2023-10-24 | Other financing | 450,000 | Form d |
| 2022-10-18 | Debt financing | 2,300,000 | Form d |
Showing 5 of 7 events.
Latest dated events (21)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-27 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 21 events.
Biomarker capability evidence (10)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| RSL1D1 | Trial sponsor | Named in trial exclusion criteria |
| SDHB | Trial sponsor | Named in trial exclusion criteria |
| SDHB | Trial sponsor | Named in trial exclusion criteria |
| SDS | Trial sponsor | Named in trial exclusion criteria |
| SDS | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 10 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.